Twist Bioscience ( (TWST) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Twist Bioscience shares came under pressure even though the company posted solid Q1 revenue of $103.7 million and raised its near‑term sales outlook to about $107–108 million. Management also lifted full‑year revenue guidance to $435–440 million and outlined improving profitability goals, including a target to reach adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 and push gross margins above 52%. The company emphasized a strategy of disciplined, scalable growth in its next-generation sequencing (NGS) and DNA synthesis (DSPS) businesses, which analysts are now reassessing in light of the sharper share price drop.
More about Twist Bioscience
YTD Price Performance: 29.48%
Average Trading Volume: 1,438,333
Technical Sentiment Signal: Buy
Current Market Cap: $2.52B
For further insights into TWST stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.